252 related articles for article (PubMed ID: 25416452)
1. Biologics as countermeasures for acute radiation syndrome: where are we now?
Singh VK; Romaine PL; Newman VL
Expert Opin Biol Ther; 2015 Apr; 15(4):465-71. PubMed ID: 25416452
[TBL] [Abstract][Full Text] [Related]
2. An update on sargramostim for treatment of acute radiation syndrome.
Singh VK; Seed TM
Drugs Today (Barc); 2018 Nov; 54(11):679-693. PubMed ID: 30539167
[TBL] [Abstract][Full Text] [Related]
3. Radiation countermeasure agents: an update (2011-2014).
Singh VK; Newman VL; Romaine PL; Wise SY; Seed TM
Expert Opin Ther Pat; 2014 Nov; 24(11):1229-55. PubMed ID: 25315070
[TBL] [Abstract][Full Text] [Related]
4. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part II. Countermeasures for limited indications, internalized radionuclides, emesis, late effects, and agents demonstrating efficacy in large animals with or without FDA IND status.
Singh VK; Garcia M; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):870-884. PubMed ID: 28657406
[TBL] [Abstract][Full Text] [Related]
5. Colony-stimulating factors for the treatment of the hematopoietic component of the acute radiation syndrome (H-ARS): a review.
Singh VK; Newman VL; Seed TM
Cytokine; 2015 Jan; 71(1):22-37. PubMed ID: 25215458
[TBL] [Abstract][Full Text] [Related]
6. γ-Tocotrienol as a Promising Countermeasure for Acute Radiation Syndrome: Current Status.
Singh VK; Hauer-Jensen M
Int J Mol Sci; 2016 May; 17(5):. PubMed ID: 27153057
[TBL] [Abstract][Full Text] [Related]
7. Medical countermeasures for unwanted CBRN exposures: part II radiological and nuclear threats with review of recent countermeasure patents.
Singh VK; Romaine PL; Newman VL; Seed TM
Expert Opin Ther Pat; 2016 Dec; 26(12):1399-1408. PubMed ID: 27610458
[TBL] [Abstract][Full Text] [Related]
8. A review of radiation countermeasures focusing on injury-specific medicinals and regulatory approval status: part I. Radiation sub-syndromes, animal models and FDA-approved countermeasures.
Singh VK; Seed TM
Int J Radiat Biol; 2017 Sep; 93(9):851-869. PubMed ID: 28650707
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Neulasta or Neupogen on H-ARS and GI-ARS Mortality and Hematopoietic Recovery in Nonhuman Primates After 10-Gy Irradiation With 2.5% Bone Marrow Sparing.
Farese AM; Bennett AW; Gibbs AM; Hankey KG; Prado K; Jackson W; MacVittie TJ
Health Phys; 2019 Mar; 116(3):339-353. PubMed ID: 30281533
[TBL] [Abstract][Full Text] [Related]
10. Survival efficacy of the PEGylated G-CSFs Maxy-G34 and neulasta in a mouse model of lethal H-ARS, and residual bone marrow damage in treated survivors.
Chua HL; Plett PA; Sampson CH; Katz BP; Carnathan GW; MacVittie TJ; Lenden K; Orschell CM
Health Phys; 2014 Jan; 106(1):21-38. PubMed ID: 24276547
[TBL] [Abstract][Full Text] [Related]
11. Nonhuman primates as models for the discovery and development of radiation countermeasures.
Singh VK; Olabisi AO
Expert Opin Drug Discov; 2017 Jul; 12(7):695-709. PubMed ID: 28441902
[TBL] [Abstract][Full Text] [Related]
12. Filgrastim for the treatment of hematopoietic acute radiation syndrome.
Farese AM; MacVittie TJ
Drugs Today (Barc); 2015 Sep; 51(9):537-48. PubMed ID: 26488033
[TBL] [Abstract][Full Text] [Related]
13. Medical Countermeasures for Radiation Exposure and Related Injuries: Characterization of Medicines, FDA-Approval Status and Inclusion into the Strategic National Stockpile.
Singh VK; Romaine PL; Seed TM
Health Phys; 2015 Jun; 108(6):607-30. PubMed ID: 25905522
[TBL] [Abstract][Full Text] [Related]
14. Radioprotective Efficacy of Gamma-Tocotrienol in Nonhuman Primates.
Singh VK; Kulkarni S; Fatanmi OO; Wise SY; Newman VL; Romaine PL; Hendrickson H; Gulani J; Ghosh SP; Kumar KS; Hauer-Jensen M
Radiat Res; 2016 Mar; 185(3):285-98. PubMed ID: 26930378
[TBL] [Abstract][Full Text] [Related]
15. Sargramostim in acute radiation syndrome.
Lazarus HM; McManus J; Gale RP
Expert Opin Biol Ther; 2022 Nov; 22(11):1345-1352. PubMed ID: 36325797
[TBL] [Abstract][Full Text] [Related]
16. Neulasta Regimen for the Hematopoietic Acute Radiation Syndrome: Effects Beyond Neutrophil Recovery.
Legesse B; Kaur A; Kenchegowda D; Hritzo B; Culp WE; Moroni M
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(4):935-944. PubMed ID: 30496878
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of amifostine for the acute radiation syndrome.
Singh VK; Seed TM
Expert Opin Drug Saf; 2019 Nov; 18(11):1077-1090. PubMed ID: 31526195
[No Abstract] [Full Text] [Related]
18. The Effect of Radiation Dose and Variation in Neupogen® Initiation Schedule on the Mitigation of Myelosuppression during the Concomitant GI-ARS and H-ARS in a Nonhuman Primate Model of High-dose Exposure with Marrow Sparing.
MacVittie TJ; Bennett AW; Farese AM; Taylor-Howell C; Smith CP; Gibbs AM; Prado K; Jackson W
Health Phys; 2015 Nov; 109(5):427-39. PubMed ID: 26425903
[TBL] [Abstract][Full Text] [Related]
19. Entolimod as a radiation countermeasure for acute radiation syndrome.
Singh VK; Seed TM
Drug Discov Today; 2021 Jan; 26(1):17-30. PubMed ID: 33065293
[TBL] [Abstract][Full Text] [Related]
20. PEG-G-CSF and L-Citrulline Combination Therapy for Mitigating Skin Wound Combined Radiation Injury in a Mouse Model.
Wang L; Zhai M; Lin B; Cui W; Hull L; Li X; Anderson MN; Smith JT; Umali MV; Jiang S; Kiang JG; Xiao M
Radiat Res; 2021 Jul; 196(1):113-127. PubMed ID: 33914884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
